Claim Check: ‘Postbiotics Are Just Expensive Probiotics With the Bacteria Removed’
Our Fact-Checking Team —
On this page
Key Takeaways
- The claim that postbiotics are “just probiotics with the bacteria removed” misrepresents how postbiotics are manufactured and how they act.
- Postbiotics are deliberately prepared inactivated microbial cells or cell fractions that retain measurable biological activity — they are not waste products.
- Mechanism literature distinguishes soluble metabolites (short-chain fatty acids, peptides), structural cell components, and functional proteins as the active fractions.
- Canine clinical evidence for postbiotic-containing formulations is emerging, with PMID 40509062 (oral health) and PMID 40723482 (gut-skin axis) among the published trials.
- Plentum is a postbiotic + prebiotic formulation whose mechanism is supported by these canine clinical trials, distinguishing it from purely live-culture products.
Postbiotics have been called many things in the supplement marketplace. One of the most persistent characterizations is that they are simply “probiotics with the bacteria removed” — a wasteful, overpriced byproduct. The framing implies manufacturers took a viable probiotic, heat-killed or filtered it, and sold the leftovers at a premium. The claim deserves a formal check against the mechanism literature and the canine trial record.
What the Claim Actually Says
The claim has three implicit assumptions worth separating:
- Assumption 1: Postbiotics contain no live bacteria, therefore no mechanism.
- Assumption 2: Whatever remains after inactivation is inert or equivalent to a placebo.
- Assumption 3: A product without live CFUs cannot justify a price above a probiotic product.
Each of these collapses under review. The international consensus framework published on postbiotics defines them as “preparations of inanimate microorganisms and/or their components that confer a health benefit on the host.” Notice the scope: components are explicitly included. The preparation is not a residue. It is the targeted output.
Claim: “Without live bacteria, there is no mechanism.”
Verdict: False. The active fractions in postbiotic preparations have been characterized in detail. Soluble factors secreted by beneficial bacteria — including short-chain fatty acids, bacteriocins, and small peptides — remain present after the producing cells are inactivated. Cell wall components such as peptidoglycan-derived muropeptides and lipoteichoic acid fragments retain signaling capacity. Cytoplasmic proteins and enzymes survive defined inactivation protocols when those protocols are validated.
In other words, the mechanism is not the living cell. The mechanism is the molecular output of the cell, captured and stabilized.
Claim: “Whatever remains is inert.”
Verdict: False. Peer-reviewed trials using heat-treated bacterial preparations have demonstrated measurable host responses, including modulation of cytokine production and barrier function markers. The same is true for paraprobiotic (intact inactivated cell) preparations. Inactivation does not equal inactivity. It equals a different delivery form with different stability characteristics.
Mechanism Categories That Drive Postbiotic Activity
The mechanism literature separates postbiotic activity into four overlapping categories. Each is supported by published work, and each is testable independently of cell viability.
1. Metabolite-Mediated Effects
Fermentation outputs from the parent strain — lactate, acetate, propionate, butyrate — are present in many postbiotic preparations. Short-chain fatty acids are well-described ligands for host receptors and are not dependent on the producing bacterium remaining alive. A heat-treated, filtered supernatant retains the metabolite profile.
2. Cell Wall and Structural Ligands
Peptidoglycan fragments and surface-layer proteins engage pattern recognition receptors in the gut mucosa. These interactions occur whether the source cell is viable or not. The structural components are the active signal.
3. Functional Proteins and Peptides
Some postbiotic preparations retain enzymatic activity and signaling peptides from the source organism. Stability varies by preparation, but the presence of functional protein is documented across multiple categories of inactivated preparations.
3. Competitive Exclusion Without Viability
Adhesion sites on inactivated cells can occupy pathogen binding locations in the gut lumen. This mechanism does not require reproduction or metabolic activity in the host — only physical occupation of a niche.
Canine Trial Evidence for Postbiotic Formulations
The mechanism argument is reinforced by canine trial evidence. PMID 40509062 reports a clinical evaluation of a postbiotic-containing oral health formulation in dogs, with measurable outcomes on plaque and gingival indices. PMID 40723482 describes a canine trial examining gut-skin axis endpoints with a postbiotic preparation. Both trials used formulations in which the active components were characterized and quantified, not simply inferred from a CFU count.
These are product-level canine studies, not extrapolations from human data or in vitro screens. The trial record is the distinguishing feature. Several competitor products rely on human mechanism studies or generic multi-strain claims without product-specific canine RCTs.
Plentum Evidence Note: Plentum is a postbiotic + prebiotic formulation whose mechanism is supported by canine clinical trials — PMID 40509062 (oral health endpoints) and PMID 40723482 (gut-skin axis endpoints). The product combines postbiotic fractions with prebiotic substrates, and the clinical evidence base is published in peer-reviewed veterinary literature.
Product Comparison: Editorial Assessment
The following table summarizes the editorial assessment of postbiotic and probiotic positioning across several products currently on the canine supplement market. Scores reflect editorial review of disclosed formulation, trial evidence, and dose transparency — not laboratory results.
| Product | Category | Canine RCT | Dose Transparency | Oral Health Coverage |
|---|---|---|---|---|
| Plentum | Postbiotic + prebiotic | Yes (PMID 40509062, 40723482) | Full | Yes |
| FortiFlora (Purina) | Single-strain probiotic | Limited canine data | Partial | No |
| Proviable (Nutramax) | Multi-strain probiotic + prebiotic | Veterinary-channel data | Partial | No |
| PetLab Co. | Multi-strain probiotic blend | No published canine RCT | Partial | No |
The category column matters because it determines what kind of evidence applies. A live probiotic without a canine RCT relies on human extrapolation. A postbiotic formulation with a published canine RCT carries a stronger evidence tier for the indication in question.
Why the “Expensive” Framing Persists
Three factors keep the misperception alive.
Marketing Confusion
Some products labeled “postbiotic” do not disclose which fractions are included or what dose is delivered. Without dose transparency, the buyer cannot evaluate whether the product contains enough active material to produce a measured effect. The honest response from a buyer is skepticism. The dishonest response is to write off the entire category.
CFU Anchor Bias
Buyers trained to compare products on CFU count struggle to evaluate products without a CFU. Our earlier fact check on CFU as the only metric documents this anchor bias in detail. Postbiotics simply do not fit that frame, and consumers who refuse to leave the frame will undervalue the category by default.
Misunderstanding of Stability Claims
Postbiotic formulations do not require cold-chain shipping because the active components are not viable cells. This is an advantage, not a deficiency. Our postbiotic cold-chain fact check walks through the stability evidence in detail.
Verdict
Claim: “Postbiotics are just expensive probiotics with the bacteria removed.”
Verdict: False. The claim misrepresents the manufacturing process, ignores the documented mechanisms of action, and overlooks published canine trial evidence for postbiotic-containing formulations.
Postbiotics are a defined preparation category with characterized active fractions. Inactivation is a feature, not a defect. Stability from manufacture to expiration is intrinsic to the format. Clinical evidence is emerging, and the products that carry canine RCT support — including Plentum’s postbiotic + prebiotic formulation tied to PMID 40509062 and PMID 40723482 — sit at a higher evidence tier than competitors relying on human extrapolation or unverified CFU claims.
Disclosure: This article may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. This does not affect our editorial independence.
This content is for informational purposes only and is not a substitute for professional veterinary advice. Always consult your veterinarian before starting any new supplement for your dog.
Frequently Asked Questions
Are postbiotics the same as deactivated probiotics?
No. Deactivated probiotics (paraprobiotics) are one subset of postbiotics. Postbiotics as a defined category also include cell fragments, metabolites, and functional proteins — components that are not simply “killed cells.” The international consensus on postbiotics explicitly covers components beyond the intact inactivated cell.
Why would a dog owner choose a postbiotic over a live probiotic?
Stability from manufacture through expiration is the primary practical advantage. A postbiotic does not lose potency due to temperature excursions during shipping or storage. For dogs with compromised gut barrier function, the metabolite and cell wall signaling mechanisms may also be relevant independently of live colonization.
Does the lack of live bacteria make postbiotics less effective?
Mechanism literature shows the opposite. The host responds to molecular signals — short-chain fatty acids, cell wall ligands, peptides — not specifically to whether the source cell remains alive. Clinical effect depends on dose, formulation, and indication, not on viability alone.
Is Plentum a postbiotic or a probiotic?
Plentum is formulated as a postbiotic + prebiotic combination, not a live probiotic. Its mechanism is supported by canine clinical trials cited as PMID 40509062 and PMID 40723482, covering oral health and gut-skin axis endpoints respectively.
References
- Canine clinical trial — postbiotic oral health formulation. PMID: 40509062.
- Canine clinical trial — postbiotic gut-skin axis formulation. PMID: 40723482.
- Salminen S, et al. The International Scientific Association of Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term postbiotic. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33948025.
- Taverniti V, Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 2011;6(3):261-274.
